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Abstract 
Bullous pemphigoid (BP) is a blistering autoimmune disease mainly observed in elderly pa-
tients. Several triggers are known for this autoimmune disease and some drugs are known to 
be a cause of BP. However, there are only few case reports on the induction of BP under ada-
limumab therapy. Other autoimmune diseases, such as lupus erythematosus, are also known 
to occur under TNF inhibition. Here, we report on an 81-year-old patient who received ada-
limumab for ulcerative colitis and subsequently developed BP. Other causes of BP (tumors, 
other drugs, viral or toxoplasma infections) were excluded. We initiated a topical and systemic 
therapy (prednisolone 1 mg/kg/day) and stopped the adalimumab injections. The patient’s 
symptoms resolved quickly and we were able to taper corticosteroid therapy. This rare case 
highlights the importance to monitor for autoimmune events during TNF inhibition. 
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Introduction 
Bullous pemphigoid (BP) is a blistering autoimmune disease mainly observed in elderly 
patients. IgG1 and IgG4 autoantibodies against the BP180/BP230 antigen, part of hemidesmo-
somes, lead to the formation of subepidermal blisters, which can form large bullae [1]. 
Several triggers have been discussed, such as drugs, vaccinations, radiotherapy, UV radi-
ation, burns, surgical procedures, and various infections [1]. Only few cases document the on-
set of BP after initiation of TNF inhibitor treatment with adalimumab. We present a patient 
who received adalimumab therapy for ulcerative colitis and consecutively developed BP. 
Case Report 
The patient (81 years old, white, 1.85 m, 105 kg) said that ulcerative colitis was diagnosed 
40 years ago. After moving houses 5 years ago, the gastrointestinal symptoms aggravated. 
Therefore, a therapy with adalimumab was initiated after an application with azathioprine 
had to be quit due to elevated liver enzymes. 
Only a few days after receiving the second out of 6 injections of the second cycle, the pa-
tient noticed a first blister located on his right arm. In the following days, more blisters – on 
both arms, on both thighs, on the abdomen, and on the back – appeared. Simultaneously, a 
slight pruritus emerged. Initially, therapy was started with topical betamethasone.  
By the time the patient presented to our clinic, numerous, coalescing, hemorrhagic lesions 
as well as scattered tense blisters on the extremities and the abdomen were seen. Figure 1 
shows the clinical appearance of the patient shortly after admission to our clinic. He had been 
taking irbesartan, bisoprolol, torasemide, atrovastatine, acetylsalicylic acid, mirtazapine, 
mesalazine, kaliumchloride, and levothyroxine for 6 years. The use of herbal medication or 
supplements as well as kidney dysfunction, dehydration, lately performed surgical proce-
dures, strenuous physical activities, or vaccinations were denied by the patient. There was no 
association between the blisters’ appearance and new drugs, other than adalimumab. A skin 
biopsy performed shortly after admission to our hospital showed a subepidermal blister with 
fibrin deposits as well as eosinophils and neutrophils within the blister. Numerous granulo-
cytes and eosinophils were also found in the upper corium (Fig. 1). 
In addition to the already mentioned skin findings, small ulcers located at both lateral 
ankles were observed. 
The laboratory findings showed an increased BP180 of 1:2,560 (reference range, <1:10). 
Tests for HHV8, hepatitis B, hepatitis C, Helicobacter pylori, and Toxoplasma gondii were neg-
ative. We initiated a therapy with 80 mg prednisolone (1 mg/kg), which we increased up to 
100 mg after 3 days as new blisters showed up. The ongoing formation of blisters during the 
first 7 days of treatment led us to adjust the immune-suppressive therapy up to 120 mg pred-
nisolone for 2 days. From day 10 on, the therapy with prednisolone was tapered. Azathioprine 
was not an option because of hepatic parenchyma damage (elevated liver enzymes after a 
therapy with azathioprine 6 months ago). Nevertheless, we started with methotrexate 15 mg 
s.c. per week on the 10th day. Although we did not presume torasemide to be the trigger for 
BP, we switched this medication to hydrochlorothiazide (HCT) 12.5 mg on day 7.  
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Discussion 
To date, there are many reported cases of drug-induced BP. Furosemide has been associ-
ated with the occurrence of BP before [2]. Although the dose of torasemide had been raised 
some weeks before the first blisters appeared, we came to the conclusion that this substance 
was not the trigger of the patient’s BP. In fact, he had been treated with torasemide before – 
for the first time in 2011. An increased dose of torasemide is very unlikely to be the cause of 
BP in this case. 
Recently Wessman et al. [3] described a 49-year-old white man with BP after undergoing 
adalimumab treatment. The first time BP was mentioned as an adverse reaction to ada-
limumab was by Stausbøl-Grøn et al. [4] in 2009. 
TNF-α inhibitors are known to increase autoantibody production [5]. The incidence of 
systemic lupus erythematosus and the exacerbations of multiple sclerosis appear to be more 
frequent in a collective undergoing TNF-α inhibitor medication.  
These findings have been explained with 2 pathomechanisms: an amount of antigens 
from apoptotic cells either leads to the formation of autoantibodies or there is an unbalanced 
cytotoxic T-cell response. Due to this disbalance, autoreactive B cells are no longer efficiently 
suppressed [6, 7]. 
These explanations are speculative, but could be taken into account for the initiation of 
BP under adalimumab medication. Nevertheless, there is no final answer and further work is 
needed in order to understand this phenomenon and to explore the pathophysiology of the 
whole process. 
The titers of antinuclear and anti-dsDNA are checked routinely during adalimumab appli-
cation in order to screen for autoimmune reactions. In line with that, Wessman et al. [3] sug-
gest to establish an additional anti-BP180 measurement under therapy with TNF-α inhibitors. 
This could promote an early detection and in consequence decline the outbreak of BP. 
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Fig. 1. Clinical presentation and H&E staining. 
 
